Nurix Therapeutics Q3 swings to profit on Roche collaboration

Overview

• Biopharma firm's Q3 revenue surged on Roche license revenue and Sanofi milestone payment

• Q3 net income swung to profit, with diluted EPS at $4.73

• Company ended Q3 with $1.1 bln in cash and runway into H2 2029

Outlook

• Company expects cash runway into the second half of 2029

• Nurix plans to expand bexobrutideg development into immune-mediated diseases, including CSU and MS

• Company plans to enroll about 30 patients per tumor type in NX-1607 expansion cohorts

Result Drivers

• COLLABORATION PAYMENTS - Surge in Q3 revenue driven mainly by Roche license revenue and Sanofi milestone payment

• COST SHARING - Lower R&D expenses attributed to cost sharing with Roche

• ONE-TIME EXPENSES - Higher G&A costs due to consulting and business development expenses related to Roche deal

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Nurix Therapeutics, Inc. is $34.00, about 52.1% above its October 9 closing price of $22.35

Reuters Recommended Reads

• Oct 12 - Bristol Myers' lung disease drug succeeds at lower dose in late-stage trial

• Oct 12 - Bristol Myers radiopharma cancer drug slows rare tumor progression in study

• Oct 12 - Pennsylvania measles death toll rises to six after Franklin County fatality

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)